Beth Chang, PhD

Background

• Pharmacologist with broad R&D and management experience
• R&D:
  • Design and construction expression vectors for protein expression/production in mammalian and E.coli systems.
  • Development of HEK and CHO-based protein production clones. Optimization and development of biochemical and cell-based assays (2D and 3D).
  • Use of human primary cells models.
  • Use of mice as model systems for oncology and inflammatory diseases.
• Management experience:
  • Personnel and project team management; liaison between departments, companies and academic institutions.
  • Reported to senior management and coordinated inter-division efforts as a project leader
  • Manage multiple projects requiring the creation of target product profiles, hosting project meetings, and determining milestone decision points.
  • Actively involved at all stages of a project
  • Managed direct and matrix reports
• Specialties:
  • Epigenetics, Oncology, Hematology, Molecular Biology, Cell Biology, Assay development, Project Management, Medical/Corporate writing, Biochemistry

Alumni News

• After graduating from UW-Madison in 2006, she received a two-year post-doctoral fellowship from the Hope Street Kids Foundation. She served as a post-doctoral fellow with Dr. Michael Cleary at the Department of Pathology at Stanford University.
• Holds Patents for: Factor VIII compositions and methods of making and using same. and Factor VIII complex with XTEN and von Willebrand factor protein, And Uses Thereof.
• Awards: Biogen BIG Award (x5): Teaming and Leading, Achieving Excellence, Living the Values, Academic scholarship and research grants (x12)

Recent Positions:

• Associate Medical Director Global Medical Affairs Gilead Sciences, Oncology and Hematology Foster City, California (2015-2017).
• Senior Manager, Global Medical Affairs at Biogen Idec (October 2013-2015)
  Today, Biogen Idec is the oldest independent biotechnology company in the world. Patients worldwide benefit every day from its industry leading multiple sclerosis (MS) products. The company’s R&D efforts are focused on bringing new therapies to market for patients with neurodegenerative diseases, autoimmune disorders and hemophilia.
  • Biogen Idec is currently in the pre-approval setting of two breakthrough hemophilia products. The Global Medical Affairs team is supporting the launch of the products world-wide.
    • Functioning as the main bridge to affiliate Hemophilia Medical Affairs groups to develop and align global strategies.
    • Support affiliate launches of Alprolix and Eloctate via linking local needs to the Global team.
    • Responsible for the development of KOL (MD and nursing), Advocacy, and Congress Strategies in collaboration with the local affiliates.
    • Maintain strong relationships with internal cross-functional teams including affiliate Medical Affairs teams, Global Commercial Strategy, Medical Research, Market Access, legal, regulatory, and compliance.
• Associate Director (October 2012-2013) – Mountain View, CA — Amunix is an early stage biopharmaceutical company aimed to produce best-in-class pharmaceutical proteins via utilizing its proprietary XTEN half life extension technology.Responsibilities
  •Manage a team of molecular biology/mammalian tissue culture scientists and research associates to support projects involving coagulation factors and metabolic peptides.
  •Host internal and external project team meetings with partner companies, determine milestone decision points and coordinate material transfers.
  •Design and construct expression vectors that encode a long-lived version of coagulation factors (e.g. FVII, FVIII, FIX) and other therapeutic proteins.
  •Expression of recombinant coagulation factors in the mammalian system and coordinate ELISA/clotting/Western blot analysis
• Ammunix Inc. is featured here for a next generation Hemophilia A drug that is under FDA review – Press Release Details. Additional Analyses from Phase 3 A-LONG Study Support Positive Clinical Profile of ELOCTATE for Hemophilia A- WESTON, Mass. and STOCKHOLM–(BUSINESS WIRE)–Jul. 4, 2013– Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi)